Trial Profile
A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Sep 2023 Results from (HZA102942,HZA112776 and HZA112777) and two Phase 2b(HZA106855 and HZA106853) assessing compare model-predicted steady-state maximumplasma concentrations (Cmax) and overall systemicexposure (AUC0-24) of FF and VI in pediatric Japaneseand non-Japanese population subgroups presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 21 May 2018 Results presented in the GlaxoSmithKline media release.
- 21 May 2018 According to a GlaxoSmithKline media release, based on the data from this trial GlaxoSmithKline has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) as maintenance treatment of asthma as prophylactic therapy in children aged 5 to 11 years (inclusive).